Fuji Pharma Co., Ltd. (4554.T) Stock
Fuji Pharma Co., Ltd.

Company profile
Fuji Pharma reported revenue of 51.68 billion JPY for fiscal year 2025, up 12.0% from fiscal year 2024, and net income of 3.00 billion JPY. That is a net profit margin of 5.8% for fiscal year 2025. Our analysis of its filings shows revenue growing from 40.89 billion JPY in fiscal year 2023 to 51.68 billion JPY in fiscal year 2025, 12.4% a year on average.
What stands out
- Net income fell 51.2% in fiscal year 2025, from 6.15 billion JPY in fiscal year 2024.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended September 30, 2025.
About Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
Largest shareholders
- Hirofumi Imai26.22 %26.22%
- Noriko Arai4.672 %4.67%
- Lotus Pharmaceutical Co., Ltd.4.59%
- Imai Family3.768 %3.77%
- SBI Asset Management Co., Ltd.3.39%
Share of the company, as of September 25, 2026
Leadership
- Shuhei Morita — President, CEO & Director, 51
- Toyoyuki Kamide — Executive VP, Head of Corporate Management & Director, 60
- Satoshi Suzuki — Executive VP, Head of Business Strategy Division & Director, 62
- Atsuya Mitsuhashi — Managing Executive Officer & Corporate Planning Department, 54
- Masayuki Naganawa — Managing Executive Officer & Head of Research and Development
How much revenue does Fuji Pharma make?
Fuji Pharma reported 51.68 billion JPY in revenue for fiscal year 2025, up 12.0% from 46.14 billion JPY in fiscal year 2024.
What companies are similar to Fuji Pharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Zeria Pharmaceutical Co., Ltd. (4559.T), Kyorin Pharmaceutical Co., Ltd. (4569.T), Aska Pharmaceutical Holdings Co.,Ltd. (4886.T), StemRIM (4599.T).
Has Fuji Pharma made a profit in recent years?
Net income by fiscal year: FY2021, 2.43 billion JPY; FY2022, 2.70 billion JPY; FY2023, 3.44 billion JPY; FY2024, 6.15 billion JPY; FY2025, 3.00 billion JPY. It was profitable in each of these years.
How has Fuji Pharma's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 33.99 billion JPY; FY2022, 35.43 billion JPY; FY2023, 40.89 billion JPY; FY2024, 46.14 billion JPY; FY2025, 51.68 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Fuji Pharma Co., Ltd. (4554.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4554.T